Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism

There are no approved drugs for the treatment of heart failure with preserved ejection fraction (HFpEF), which is characterized by left ventricular (LV) diastolic dysfunction. We demonstrate that ITF2357 (givinostat), a clinical-stage inhibitor of histone deacetylase (HDAC) catalytic activity, is ef...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Transl Med
Main Authors: Jeong, Mark Y., Lin, Ying H., Wennersten, Sara A., Demos-Davies, Kimberly M., Cavasin, Maria A., Mahaffey, Jennifer H., Monzani, Valmen, Saripalli, Chandrasekhar, Mascagni, Paolo, Reece, T. Brett, Ambardekar, Amrut V., Granzier, Henk L., Dinarello, Charles A., McKinsey, Timothy A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5908215/
https://ncbi.nlm.nih.gov/pubmed/29437146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aao0144
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados